Novo Nordisk sues Eli Lilly over GLP-1 ads

Novo Nordisk has taken legal action against Eli Lilly, alleging that the rival pharmaceutical company's ads for its diabetes and weight-loss drugs, Zepbound and Mounjaro, are misleading. Specifically, Novo Nordisk claims Eli Lilly's ads unfairly compare the highest doses of its drugs against lower doses used by Novo Nordisk's similar medication. This lawsuit underscores the intense competition in the GLP-1 drug market, which has seen significant growth due to their effectiveness in managing diabetes and aiding weight loss. The outcome could impact how these companies market their products and influence the broader healthcare industry's approach to treatment strategies.